Sio Gene Therapies, Inc. focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease.
Market Cap | 25.44 Million | Shares Outstanding | 73.739 Million | Avg 30-day Volume | 171.557 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.29 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -71.001 Million |
Price to Book Value | 0.8128 | Operating Margin | 0.0 | Enterprise Value | -15.861 Million |
Current Ratio | 5.517 | EPS Growth | -0.581 | Quick Ratio | 4.902 |
1 Yr BETA | 1.1023 | 52-week High/Low | 2.66 / 0.23 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -29.5284 | Altman Z-Score | -16.3048 | Free Cash Flow to Firm | -41.194 Million |
Earnings Report | 2022-08-11 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
NASSIF DAVID W. INTERIM CEO, CFO |
|
546,500 | 2022-02-08 | 2 |
MESWANI PARAG V CHIEF COMMERCIAL OFFICER |
|
153,700 | 2022-02-08 | 2 |
CHERUVU PAVAN CHIEF EXECUTIVE OFFICER |
|
278,242 | 2021-12-08 | 1 |
|
42,000 | 2021-04-15 | 0 | |
|
42,000 | 2021-04-15 | 0 | |
|
42,000 | 2021-04-15 | 0 | |
|
42,000 | 2021-04-15 | 0 | |
CORCORAN GAVIN CHIEF R&D OFFICER |
|
244,300 | 2021-04-15 | 0 |
|
42,000 | 2021-04-15 | 0 | |
|
18,577,380 | 2020-02-24 | 0 | |
|
0 | 2020-02-17 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
No longer subject to file | 2019-07-10 | 0 |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
0 | 2019-04-15 | 0 | |
|
0 | 2019-04-15 | 0 | |
|
0 | 2019-04-15 | 0 | |
BAZLEY MATHEW C. GENERAL COUNSEL |
|
0 | 2019-04-15 | 0 |
|
99,285,714 | 2019-01-01 | 0 | |
LOMBARDO ILISE CHIEF MEDICAL OFFICER |
|
0 | 2018-08-15 | 0 |
|
0 | 2018-06-06 | 0 | |
WEINHOFF GREGORY M PRINCIPAL FINANCIAL OFFICER |
|
0 | 2018-03-15 | 0 |
ALTMEYER MARK PRES (ASG) & CHIEF COMM. OFC. |
|
0 | 2018-03-15 | 0 |
MOHR STEPHEN FREDERICK GENERAL COUNSEL |
|
0 | 2018-03-15 | 0 |
HUNG DAVID PRINCIPAL EXECUTIVE OFFICER |
|
0 | 2017-12-29 | 0 |
|
75,000,000 | 2017-09-06 | 0 | |
|
75,000,000 | 2017-07-01 | 0 | |
|
0 | 2017-05-15 | 0 | |
|
0 | 2017-05-15 | 0 | |
FRIEDHOFF LAWRENCE MD PHD CHIEF DEVELOPMENT OFFICER |
|
0 | 2017-04-28 | 0 |
|
0 | 2017-04-28 | 0 | |
ADASCZIK MICHAEL PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2017-04-28 | 0 |
|
0 | 2017-04-28 | 0 | |
MCCOURT MARION PRINCIPAL OPERATING OFFICER |
|
0 | 2017-04-07 | 0 |
|
75,000,000 | 2016-07-08 | 0 | |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
75,000,000 | 2016-07-08 | 0 |
|
75,000,000 | 2016-07-08 | 0 | |
|
75,000,000 | 2016-07-08 | 0 | |
CVIJIC CHRISTINE MIKAIL CHIEF ADMIN OFFICER AND GC |
|
0 | 2016-04-29 | 0 |
RAMASWAMY VIVEK PRINCIPAL EXECUTIVE OFFICER |
|
0 | 2016-04-29 | 0 |
ROMEO MARIANNE L. HEAD,GLOBAL TRANS & RISK MGMT |
|
0 | 2016-04-29 | 0 |
ROEMER ALAN S. PRINCIPAL FIN & ACCT OFFICER |
|
0 | 2015-06-10 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
SIO GENE THERAPIES INC SIOX | 2022-08-11 22:15:03 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 21:45:04 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 21:15:03 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 20:45:04 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 20:15:03 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 19:45:04 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 19:15:05 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 18:45:03 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 18:15:05 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 17:45:05 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 17:15:05 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 16:45:04 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 16:15:05 UTC | 0.9115 | 1.4085 | 2400000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 15:45:05 UTC | 0.9115 | 1.4085 | 1700000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 15:15:03 UTC | 0.9115 | 1.4085 | 1700000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 14:45:06 UTC | 0.9115 | 1.4085 | 1700000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 14:15:04 UTC | 0.9115 | 1.4085 | 1700000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 13:45:04 UTC | 0.8152 | 1.5048 | 1700000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 13:15:04 UTC | 0.8152 | 1.5048 | 1700000 |
SIO GENE THERAPIES INC SIOX | 2022-08-11 12:45:04 UTC | 0.8152 | 1.5048 | 1700000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|